Benjamin Ascher News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Benjamin Ascher. Real-time updates on events, politics, business and more.

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications -Today at 12:08 pm

August 30, 2023

Analyses of pivotal study data of Dysport® reveal a large proportion of study patients did not require retreatment for at least 12 weeks This new analysis...

United Kingdom United States France General Frederic Bard Renaud Morin Jorge Jacinto

Source: marketscreener.com

Galderma to Present Extensive New Clinical Data Across Its Portfolio of Neuromodulators, Fillers and Biostimulators at the IMCAS World Congress 2022

May 31, 2022

Strong clinical data supporting Alluzience (abobotulinumtoxinA, ABO), the first liquid, ready-to-use neuromodulator as an effective and well-tolerated treatment for glabellar (frown) lines, with

United States France General South Korea Brenda Latowsky Andreas Nikolis Benjamin Ascher

Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Benjamin Ascher News Today

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport&#xAE; (abobotulinumtoxinA) in five therapeutic indications -Today at 12:08 pm

Galderma to Present Extensive New Clinical Data Across Its Portfolio of Neuromodulators, Fillers and Biostimulators at the IMCAS World Congress 2022

Explore More Categories

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications -Today at 12:08 pm